| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
(R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine manufacturers
- AHR antagonist 5
-
- $1520.00
-
2026-04-22
- CAS:2247953-39-3
- Purity:
- Supply Ability: 10g
- AHR antagonist 5
-
- $1520.00
-
2025-07-17
- CAS:2247953-39-3
- Purity:
- Supply Ability: 10g
|
| | (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine Basic information |
| Product Name: | (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine | | Synonyms: | (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine;AHR antagonist 5 | | CAS: | 2247953-39-3 | | MF: | C25H25ClFN7 | | MW: | 477.97 | | EINECS: | | | Product Categories: | | | Mol File: | 2247953-39-3.mol | ![(R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine Structure](CAS/20210111/GIF/2247953-39-3.gif) |
| | (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine Chemical Properties |
| storage temp. | Store at -20°C | | form | Solid | | color | Yellow to orange | | InChIKey | BCXFADDZDWTXMZ-VOPAOICTNA-N | | SMILES | N([C@@H]1CCC2NC3=CC=CC=C3C=2C1)C1=NC(C2=CN=CC(F)=C2)=NC2=C(C(C)C)C=NN12.Cl |&1:1,r| |
| | (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine Usage And Synthesis |
| Uses | AHR antagonist 5, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC50 of < 0.5 μΜ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint inhibitor anti-PD-1[1]. | | Biological Activity | AHR antagonist 5, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC50 of < 0.5 μμ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint inhibitor anti-PD-1[1].
Tumor growth inhibition is statistically significant with AHR antagonist 5 as single. AHR antagonist 5 (10 mg/kg; p.o.; every day for 3 weeks) combination with anti-PD-1 significantly inhibited tumor growth inhibition compared to the anti-PD-1 alone[1]. | | in vivo | Tumor growth inhibition is statistically significant with AHR antagonist 5 as single. AHR antagonist 5 (10 mg/kg; p.o.; every day for 3 weeks) combination with anti-PD-1 significantly inhibited tumor growth inhibition compared to the anti-PD-1 alone[1]. | Animal Model: | Balb/c Mice (Mouse Colorectal Cancer Model CT26)[1] | | Dosage: | 10 mg/kg (combination with anti-PD-1) | | Administration: | P.o.; every day for 3 weeks | | Result: | Significantly inhibited tumor growth inhibition.
|
| | References | [1]. Alfredo C. Castro, et al. Indole ahr inhibitors and uses thereof. WO2018195397A2. |
| | (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine Preparation Products And Raw materials |
|